MAP Pharma’s New Drug Application for Levadex Accepted for Review
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Migraine.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
Clinical Trials.gov: Understanding Clinical Trials | MAP Pharmaceuticals: Inhaled Migraine Therapy | MAP Pharma Gets FDA Acceptance to File Levadex NDA | FDA: New Drug Application (NDA)